COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Over the past year, CMPS stock has been going nowhere fast. However, there's been recent progress in advancing psilocybin-assisted therapy.

Compass Pathways Offers Chance on Exploratory Mental Health Treatments

Compass Pathways (NASDAQ:CMPS), a company researching psychedelics for mental health treatment, released its financial statement for the first quarter of 2021. The company, currently pushing psilocybin through a phase 2b clinical trial, highlighted the issuing of two new patents and a post-quarter equity financing round of $144 million.

Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts

LONDON, May 13, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2021 and gave an update on recent progress across its business.

COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021

Mind Medicine MindMed

Psychedelics could be a game-changer for millions struggling with mental health. Here are some of the top ways to trade psychedelic stocks.

3 Top Psychedelic Stocks to Own Now

London, UK, May 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2021, and provide an update on recent business developments, on 13 May 2021.

COMPASS Pathways plc to announce first quarter 2021 financial results on 13 May 2021

Apollo Medical Hlds

Avantor Inc.

GoodRx Holdings

5 Top Medical Services Stocks to Beat COVID-Led Industry Challenges

London, UK, April 27, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share.

COMPASS Pathways launches proposed public offering

The Shroom Boom Is Here. Buy CMPS Stock to Ride This Explosive Megatrend.

Magic mushrooms and other hallucinogens are becoming a big business.

If You Missed the Cannabis Stock Gold Rush, Try This New Industry Instead

These psychedelic stocks are the sector's needle-movers and have the potential to make a big splash this year The post 3 of the Top Psychedelic Stocks That Will Blow Your Mind appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

3 of the Top Psychedelic Stocks That Will Blow Your Mind

Study concludes that psilocybin findings should be explored further in larger studies Study concludes that psilocybin findings should be explored further in larger studies

New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder

London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor meetings.

COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference

COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors

Market participants are underestimating COMP360 probabilities of success in rNPV-models.

Compass Pathways: rNPV Probabilities Of Success Are Underestimated

American Well Corporation

Athira Pharma

Broadstone Net Lease

Coupang

Dyne Therapeutics

GreenBox POS

908 Devices

Metacrine

Outset Medical

Poshmark

Pactiv Evergreen

StepStone Group

Sumo Logic

Vitru Limited

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.

U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week

Illumina

Johnson & Johnson

Pfizer

ResMed

Teladoc

Thermo Fisher Scientific

These steady, strong healthcare stocks are great picks for investors to buy and hold onto for at least the next five years. The post 7 Healthcare Stocks to Buy and Hold for the Long Term appeared first on InvestorPlace.

7 Healthcare Stocks to Buy and Hold for the Long Term

Highlights include continued progress with phase IIb psilocybin therapy clinical trial, launch of first Centre of Excellence, and expansion of Discovery Center Highlights include continued progress with phase IIb psilocybin therapy clinical trial, launch of first Centre of Excellence, and expansion of Discovery Center

COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020

1-800-FLOWERS.COM

Tesla

Three stocks are rich in growth potential, but everyone is afraid of buying them.

3 Outside-the-Box Stocks to Buy Now

New York, March 02, 2021 (GLOBE NEWSWIRE) -- London, UK – 2 March 2021

COMPASS Pathways plc to announce fourth quarter and full year 2020 financial results on 9 March 2021

The buzz surrounding psychedelic therapies is only going to grow over time.

Investing $1,000 in These 2 Psychedelic Stocks Is an Absurdly Smart Move

New York, NY, Feb. 26, 2021 (GLOBE NEWSWIRE) -- George Goldsmith, Chairman & CEO, to participate in Neuropsych Panel discussion

COMPASS Pathways plc to participate in Cowen's 41st Annual Health Care Conference

Aikido Pharma Inc.

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- The emergence of psychedelics as a mental health solution and as a legitimate industry has been one of the most radical market developments that we have seen in decades. Far from being a fleeting trend, the global psychedelics market is primed to...

First Movers in the Psychedelics Space Position Themselves as Industry Leaders

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists

COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy

Psychedelic stocks could have another “far out” year ahead with U.S. FDA support, as well as more clinical trials that are under way. The post 5 Groovy Psychedelic Stocks to Buy appeared first on InvestorPlace.

News for COMPASS Pathways Stock (CMPS)